WARRANTS TO PURCHASE COMMON STOCK (Details Narrative) |
9 Months Ended |
|---|---|
|
Sep. 30, 2025
$ / shares
shares
| |
| Warrants To Purchase Common Stock | |
| Number of warrants that became exercisable | shares | 13,666 |
| Exercise price of warrants became exercisable (in dollars per share) | $ / shares | $ 1,056 |
| Number of warrants that became exercisable upon FDA acceptance of NDA filing | shares | 5,758 |
| Exercise price of warrants became exercisable upon FDA acceptance of NDA filing (in dollars per share) | $ / shares | $ 1,776 |
| Number of warrants expired | shares | 1 |
| Exercise price of warrants expired (in dollars per share) | $ / shares | $ 364,800 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The exercise price of expired warrants. No definition available.
|
| X | ||||||||||
- Definition The exercise price of warrants that became exercisable during the period. No definition available.
|
| X | ||||||||||
- Definition The exercise price of warrants that became exercisable upon FDA acceptance of NDA filing during the period. No definition available.
|
| X | ||||||||||
- Definition Net number of non-option equity instruments that became exercisable. No definition available.
|
| X | ||||||||||
- Definition Net number of non-option equity instruments that became exercisable upon FDA acceptance of NDA filing. No definition available.
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|